Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-11-14
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 1717223 NOK
Award criteria: Lowest price

Technical requirements: Voluntary ex-ante transparency notice - Additional contracts for LIS 2301d ureg, ATC codes C05BB02, J01GB03, S01EA03, S01XA20 and V04CL
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for Parenteral special pharmaceutical preparations (LIS 2301d). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
53 J01GB03 Gentamicin Implant/ instillation 208400 Septopal-20er-Minikette specific Chain for implantation 1.7 mg/ball
53 J01GB03 Gentamicin Implant/ instillation 331498 Septopal-30er-Kette specific Chain for implantation 4.5 mg/ball
53 J01GB03 Gentamicin Implant/ instillation 366653 Septopal-10er-Kette specific Chain for implantation 4.5 mg/ball
146 V04CL Various allergens (36) Topical plaster/sponge/cloth 355112 True Test 36 specific Plasters til provocation tests. There is still a need to sign contracts.
Due to this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Specific Pharma A/S (the Supplier) as an additional contract to LIS 2301d, i.e., the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new competition being held for this ingredient. The health trusts that are under the regional health authorities have options for enter the agreements. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has explored the market situation and is of the opinion that it is impossible to carry out a new invitation to tender, or that a supplier other than Specific Pharma AS can deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to carry out the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this contract award are submitted before the expiry of the waiting period, set to 10 days after the publication of the Voluntary ex ante transparency notice. If no objections are received, contracts will be signed after the waiting period has expired.
LIS has explored the market situation and is of the opinion that it is impossible to carry out a new invitation to tender, or that a supplier other than Specific Pharma AS can deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to carry out the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.


Winner: Specific Pharma A/S
Award value: 1717223